Recommended Literature

Here is a list of publications featuring developmental advances and interesting applications of the products we manufacture at BV Cyclotron VU.
(Click on the PMID to see abstracts from PubMed/NCBI)

[1] PET – general
[2] [18F]FDG PET
[3] Sodium Iodide [124I] and Iodine-124
[4] Zirconium-89 and immuno-PET
[5] [18F]Fluoromethylcholine
[6] [18F]Florbetaben
[7] Prof. van Dongen and colleagues from the Imaging Center of the VU University Medical Center, Amsterdam (for a complete list of Prof. van Dongen’s publications, see here.)
[8] EATRIS
[9] Others

—-

[1] PET – general

Connors JM. Positron emission tomography in the management of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:317-22. PMID: 22160052.



Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9226-33.PMID: 10922074.


[2] FDG PET

Farquharson AL, Chopra A, Ford A, Matthews S, Amin SN, De Noronha R. Incidental focal colonic lesions found on (18)Fluorodeoxyglucose positron emission tomography/computed tomography scan: further support for a national guideline on definitive management. Colorectal Dis. 2012 Feb;14(2):e56-63. PMID: 21831171.

Alauddin MM. Positron emission tomography (PET) imaging with 18F-based radiotracers (Review Article). Am J Nucl Med Mol Imaging 2012;2(1):55-76.
Free preview article available for download here.

L Giovanella. Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas (Special Report). Expert Review of Endocrinology & Metabolism. January 2012, Vol. 7, No. 1, Pages 35-43.

Yamashita H, Kubota K, Takahashi Y, Minaminoto R, Morooka M, Ito K, Kano T, Kaneko H, Takashima H, Mimoiri A. Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis. Mod Rheumatol. 2011 Dec 29. [Epub ahead of print] PMID: 22205118.

Safar V, Dupuis J, Itti E, Jardin F, Fruchart C, Bardet S, Véra P, Copie-Bergman C, Rahmouni A, Tilly H, Meignan M, Haioun C. Interim [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab. J Clin Oncol. 2011 Dec 12. [Epub ahead of print]. PMID: 22162590.

Kao YH, Lim SS, Ong SC, Padhy AK. Thyroid Incidentalomas on Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography: Incidence, Malignancy Risk, and Comparison of Standardized Uptake Values. Can Assoc Radiol J. 2011 Dec 2. [Epub ahead of print]. PMID: 22136969.

Robertson R, Germanos MS, Manfredi MG, Smith PG, Silva MD. Multimodal imaging with 18F-FDG PET and Cerenkov luminescence imaging after MLN4924 treatment in a human lymphoma xenograft model. J Nucl Med. 2011 Nov;52(11):1764-9. PMID: 21994410.

Asabella AN, Cimmino A, Altini C, Notaristefano A, Rubini G. 18F-FDG positron emission tomography/computed tomography and \99mTc-MDP skeletal scintigraphy in a case of Erdheim-Chester disease. Hell J Nucl Med. 2011 Sep;14(3):311-2. PMID: 22087457.

Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):181-200. PMID: 19915839.


[3] Sodium Iodide [124I] and 124I

Schwartz J, Humm JL, Divqi CR, Larson SM, O’Donoghue JA. Bone Marrow Dosimetry Using 124I-PET. J Nucl Med. 2012 Mar 13. [Epub ahead of print] PMID: 22414633.

Seo Y, Gustafson WC, Dannoon SF, Nekritz EA, Lee CL, Murphy ST, Vanbrocklin HF, Hernandez-Pampaloni M, Haas-Kogan DA, Weiss WA, Matthay KK. Tumor Dosimetry Using [(124)I]m-iodobenzylguanidine MicroPET/CT for [(131)I]m-iodobenzylguanidine Treatment of Neuroblastoma in a Murine Xenograft Model. Mol Imaging Biol. 2012 Mar 2. [Epub ahead of print] PMID: 22382618.

O’Donoghue JA, Smith-Jones PM, Humm JL, Ruan S, Pryma DA, Jungbluth AA, Divgi CR, Carrasquillo JA, Pandit-Taskar N, Fong Y, Strong VE, Kemeny NE, Old LJ, Larson SM. 124I-huA33 Antibody Uptake Is Driven by A Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET. J Nucl Med. 2011 Nov 8. [Epub ahead of print] PMID: 22068895.

Nagarajah J, Jentzen W, Hartung V, Rosenbaum-Krumme S, Mikat C, Heusner TA, Antoch G, Bockisch A, Stahl A. Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck. Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1862-8. PMID: 21739331.

Chacko AM, Divgi CR. Radiopharmaceutical chemistry with iodine-124: a non-standard radiohalogen for positron emission tomography. Med Chem. 2011 Sep 1;7(5):395-412. PMID: 21711220.

Carrasquillo JA, Pandit-Taskar N, O’Donoghue JA, Humm JL, Zanzonico P, Smith-Jones PM, Divgi CR, Pryma DA, Ruan S, Kemeny NE, Fong Y, Wong D, Jaggi JS, Scheinberg DA, Gonen M, Panageas KS, Ritter G, Jungbluth AA, Old LJ, Larson SM. 124I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011 Aug;52(8):1173-80. PMID: 21764796.

Lubberink M, Herzog H. Quantitative imaging of 124I and 86Y with PET. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S10-8. PMID: 21484385.

Sgouros G, Hobbs RF, Atkins FB, Van Nostrand D, Ladenson PW, Wahl RL. Three-dimensional radiobiological dosimetry (D-RD) with 124I PET for 131I therapy of thyroid cancer. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S41-7. PMID: 21484384.

Lopci E, Chiti A, Castellani MR, Pepe G, Antunovic L, Fanti S, Bombardieri E. Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S28-40. PMID: 21484381.

Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ. Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S48-56. PMID: 21484380.

Schmitz J. The production of [124I]iodine and [86Y]yttrium. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S4-9. PMID: 21484376.

Kemerink GJ, Visser MG, Franssen R, Beijer E, Zamburlini M, Halders SG, Brans B, Mottaghy FM, Teule GJ. Effect of the positron range of 18F, 68Ga and 124I on PET/CT in lung-equivalent materials. Eur J Nucl Med Mol Imaging. 2011 May;38(5):940-8. PMID: 21287170.

Pryma DA, O’Donoghue JA, Humm JL, Jungbluth AA, Old LJ, Larson SM, Divgi CR. Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250. J Nucl Med. 2011 Apr;52(4):535-40. PMID: 21421715.

Freudenberg LS, Jentzen W, Petrich T, Frömke C, Marlowe RJ, Heusner T, Brandau W, Knapp WH, Bockisch A. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2267-76. PMID: 20661558.

Tijink BM, Perk LR, Budde M, Stigter-van Walsum M, Visser GW, Kloet RW, Dinkelborg LM, Leemans CR, Neri D, van Dongen GA. 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1235-44. PMID: 19259661.

Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E; European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging.2008 Oct;35(10):1941-59. PMID: 18670773.

Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2008 Jun;49(6):1017-23. PMID: 18483099.

Pentlow KS, Graham MC, Lambrecht RM, Daghighian F, Bacharach SL, Bendriem B, Finn RD, Jordan K, Kalaigian H, Karp JS, Robeson WR, Larson SM. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996 Sep;37(9):1557-62. PMID: 8790218.


[4] Zirconium-89 and immuno-PET

Natarajan A, Habte F, Gambhir SS. Development of A Novel Long-Lived ImmunoPET Tracer for Monitoring Lymphoma Therapy in a Humanized Transgenic Mouse Model. Bioconjug Chem. 2012 May 23. [Epub ahead of print] PMID: 22621257.

Ulmert D, Evans MJ, Holland JP, Rice SL, Wonqvipat J, Pettersson K, Abrahamsson P-A, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyer CL. Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen. Cancer Discov. 2012 Apr;2(4):320-7. Epub 2012 Mar 31. PMID: 22576209.

Williams SP. Tissue Distribution Studies of Protein Therapeutics Using Molecular Probes: Molecular Imaging. AAPS J. 2012 Mar 31. [Epub ahead of print] PMID: 22467336.

Rizni SN, Visser OJ, Vosjan MJ, van Lingen A, Hoekstra OS, Zijlstra JM, Huijgens PC, van Dongen GA, Lubberink M. Biodistribution, radiation dosimetry and scouting of (90)Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using (89)Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging. 2012 Mar; 39(3):512-20. PMID: 22218876.

Gaykema SB, Brouwers AH, Hovenga S, Lub-de Hooge MN, de Vries EG, Schröder CP. Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer. J Clin Oncol. 2012 Feb 20;30(6):e74-5. PMID: 22203768.

Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GA.
Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther. 2012 Feb 7. [Epub ahead of print] PMID: 22319202.

Nayak TK, Garmestani K, Milenic DE, Brechbiel MW. PET and MRI of Metastatic Peritoneal and Pulmonary Colorectal Cancer in Mice with Human Epidermal Growth Factor Receptor 1-Targeted 89Zr-Labeled Panitumumab. J Nucl Med. 2012 Jan;53(1):113-20. PMID: 22213822.

Hong H, Severin GW, Yang Y, Engle JW, Zhang Y, Barnhart TE, Liu G, Leigh BR, Nickles RJ, Cai W. Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):138-48. PMID: 21909753. Zhang Y, Hong H, Engle JW, Yang Y, Theuer CP, Barnhart TE, Cai W. Positron Emission Tomography and Optical Imaging of Tumor CD105 Expression with a Dual-Labeled Monoclonal Antibody. Mol Pharm. 2012 Jan 31. [Epub ahead of print] PMID: 22292418.

Oude Munnink TH, Arjaans ME, Timmer-Bosscha H, Schröder CP, Hesselink JW, Vedelaar SR, Walenkamp AM, Reiss M, Gregory RC, Lub-de Hooge MN, de Vries EG. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models. J Nucl Med. 2011 Dec;52(12):2001-8. Epub 2011 Nov 9. PMID: 22072706.

Leung K. 89Zr-Desferrioxamine-anti-CD105 TRC105 chimeric monoclonal antibody. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2011. 2011 Nov 01 [updated 2012 Jan 12]. PMID: 22259815.

Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, Lewis JS, Grimm J. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med. 2011 Oct;52(10):1608-15. Epub 2011 Sep 9. PMID: 21908391.

Dijkers E. Development of new radiopharmaceuticals for molecular imaging in oncology. PhD dissertation. University of Groningen, Netherlands. October 2011.
The dissertation can be downloaded here.

Severin GW, Engle JW, Barnhart TE, Nickles RJ. 89Zr radiochemistry for positron emission tomography. Med Chem. 2011 Sep;7(5):389-94. PMID: 21711221.

Heuveling DA, Visser GW, Baclayon M, Roos WH, Wuite GJ, Hoekstra OS, Leemans CR, de Bree R, van Dongen GA. 89Zr-nanocolloidal albumin-based PET/CT lymphoscintigraphy for sentinel node detection in head and neck cancer: preclinical results. J Nucl Med. 2011 Oct;52(10):1580-4. Epub 2011 Sep 2. PMID: 21890880.

van Dongen GA, Vosjan MJ. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm. 2010 Aug;25(4):375-85. PMID: 20707716.

Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010 Aug;51(8):1293-300. PMID: 20660376.

Hoeben BA, Kaanders JH, Franssen GM, Troost EG, Rijken PF, Oosterwijk E, van Dongen GA, Oyen WJ, Boerman OC, Bussink J. PET of hypoxia with 89Zr-labeled \cG250-F(ab’)2 in head and neck tumors. J Nucl Med. 2010 Jul;51(7):1076-83. PMID: 20554724.

Vugts DJ, van Dongen GAMS. 89Zr-labeled compounds for PET imaging guided personalized therapy. Drug Discovery Today: Technologies – Imaging Techniques. Volume 8, Issues 2–4, Summer 2011, Pages e53–e61.

Cohen R, Stammes MA, de Roos IHC, Stigter-van Walsum M, Visser GWM, van Dongen GAMS. Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets. EJNMMI Research 2011, 1:31. PMID: 22214225.

McCabe KE, Wu AM. Positive progress in immunoPET—not just a coincidence. Cancer Biother Radiopharm. 2010 Jun;25(3):253-61. PMID: 20578830.

Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schröder CP, Lub-de Hooge MN, de Vries EG. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010 May;87(5):586-92. PMID: 20357763.

Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, de Jong JR, Jensen MR, Quadt C, Garcia-Echeverria C, van Dongen GA, Lub-de Hooge MN, Schröder CP, de Vries EG. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med. 2010 May;51(5):761-7. PMID: 20395337.

Tinianow JN, Gill HS, Ogasawara A, Flores JE, Vanderbilt AN, Luis E, Vandlen R, Darwish M, Junutula JR, Williams SP, Marik J. Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol. 2010 Apr;37(3):289-97. PMID: 20346868.

Perk LR, Vosjan MJ, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):250-9. PMID: 19763566.

Holland JP, Williamson MJ, Lewis JS. Unconventional nuclides for radiopharmaceuticals. Mol Imaging. 2010 Feb;9(1):1-20. PMID: 20128994.

Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5(4):739-43. PMID: 20360768.

Börjesson PK, Jauw YW, de Bree R, Roos JC, Castelijns JA, Leemans CR, van Dongen GA, Boellaard R. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody \U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009 Nov;50(11):1828-36. PMID: 19837762.

Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009 Oct;36(7):729-39. PMID: 17631557.

Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, de Jong JR, de Vries EG, Lub-de Hooge MN. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immuno-PET imaging. J Nucl Med. 2009 Jun;50(6):974-81. PMID: 19443585.

Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG, Lambin P. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009 Jan;50(1):123-31. PMID: 19091906.

Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody \DN30. Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1857-67. PMID: 18491091.

van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007 Dec;12(12):1379-89. PMID: 18165614.

Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007 Aug;48(8):1313-9. PMID: 17631557.

Perk LR, Visser OJ, Stigter-van Walsum M, Vosjan MJ, Visser GW, Zijlstra JM, Huijgens PC, van Dongen GA. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1337-45. PMID: 16832633.

Börjesson PK, Jauw YW, Boellaard R, de Bree R, Comans EF, Roos JC, Castelijns JA, Vosjan MJ, Kummer JA, Leemans CR, Lammertsma AA, van Dongen GA. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody \U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2133-40. PMID: 16609026.

Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003 Aug;44(8):1271-81. PMID: 12902418.


[5] [18F]Fluoromethylcholine

Hara T, Koasaka N. Development of 18F-Fluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 43:187–199, 2002. PMID: 11850483.

Schoeder H, Larson S. Positron emission tomography for prostate, bladder and renal cancer. Sem Nucl Med 34:274-292, 2004. PMID: 15493005.

DeGrado T, Baldwin S. Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42:1805-1814, 2001. PMID: 11752077.

Picchio M, Messa C. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose- positron emission tomography. J Urol 169:1337-1340, 2003. PMID: 12629355.

de Jong IJ, Pruim J, Elsinga PH, et al. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44:32-38, 2003; discussion 38-39. PMID: 12814672.


[6] [18F]Florbetaben

Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O’Keefe G, Chan JG, Young K, Tochon-Danguy H, Masters CL, Rowe CC. Comparison of (11)C-PiB and (18)F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):983-9. Epub 2012 Mar 8. PMID: 22398958.

Fodero-Tavoletti MT, Brockschnieder D, Villemagne VL, Martin L, Connor AR, Thiele A, Berndt M, McLean CA, Krause S, Rowe CC, Masters CL, Dinkelborg L, Dyrks T, Cappai R. In vitro characterization of [(18)F]-florbetaben, an Aβ imaging radiotracer.Nucl Med Biol. 2012 Apr 11. [Epub ahead of print] PMID: 22503458.

Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, Eggers B, Sattler B, Schildan A, Hesse S, Meyer PM, Wolf H, Zimmermann T, Reischl J, Rohde B, Gertz HJ, Reininger C, Sabri O. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1702-14. PMID: 21547601.

Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer’s disease. Lancet Neurol. 2011 Jul;10(7):667-70. PMID: 21683932.

Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; Florbetaben Study Group. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011 May;10(5):424-35. PMID: 21481640.

O’Keefe GJ, Saunder TH, Ng S, Ackerman U, Tochon-Danguy HJ, Chan JG, Gong S, Dyrks T, Lindemann S, Holl G, Dinkelborg L, Villemagne V, Rowe CC. Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med. 2009 Feb;50(2):309-15. PMID: 19164222.

Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008 Feb;7(2):129-35. PMID: 18191617.


[7] Prof. van Dongen and colleagues from the
Imaging Center of the VU University Medical Center, Amsterdam


Rizni SN, Visser OJ, Vosjan MJ, van Lingen A, Hoekstra OS, Zijlstra JM, Huijgens PC, van Dongen GA, Lubberink M. Biodistribution, radiation dosimetry and scouting of (90)Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using (89)Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging. 2012 Mar; 39(3):512-20. PMID: 22218876.

Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GA.
Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther. 2012 Feb 7. [Epub ahead of print] PMID: 22319202.

van Dongen GA, Poot AJ, Vugts DJ. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol. 2012 Jun;33(3):607-15. Epub 2012 Jan 21. PMID: 22270450.

Heuveling DA, Visser GW, Baclayon M, Roos WH, Wuite GJ, Hoekstra OS, Leemans CR, de Bree R, van Dongen GA. 89Zr-nanocolloidal albumin-based PET/CT lymphoscintigraphy for sentinel node detection in head and neck cancer: preclinical results. J Nucl Med. 2011 Oct;52(10):1580-4. Epub 2011 Sep 2. PMID: 21890880.

Vugts DJ, van Dongen GAMS. 89Zr-labeled compounds for PET imaging guided personalized therapy. Drug Discovery Today: Technologies – Imaging Techniques. Volume 8, Issues 2–4, Summer 2011, Pages e53–e61.

Cohen R, Stammes MA, de Roos IHC, Stigter-van Walsum M, Visser GWM, van Dongen GAMS. Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets. EJNMMI Research 2011, 1:31. PMID: 22214225.

van Dongen GA, Vosjan MJ. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm. 2010 Aug;25(4):375-85. Review. PMID: 20707716.

Hoeben BA, Kaanders JH, Franssen GM, Troost EG, Rijken PF, Oosterwijk E, van Dongen GA, Oyen WJ, Boerman OC, Bussink J. PET of hypoxia with 89Zr-labeled \cG250-F(ab’)2 in head and neck tumors. J Nucl Med. 2010 Jul;51(7):1076-83. PMID: 20554724.

Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schröder CP, Lub-de Hooge MN, de Vries EG. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010 May;87(5):586-92. PMID: 20357763.

Perk LR, Vosjan MJ, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):250-9. PMID: 19763566.

Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5(4):739-43. PMID: 20360768.

Börjesson PK, Jauw YW, de Bree R, Roos JC, Castelijns JA, Leemans CR, van Dongen GA, Boellaard R. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody \U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009 Nov;50(11):1828-36. PMID: 19837762.

Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, de Jong JR, de Vries EG, Lub-de Hooge MN. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009 Jun;50(6):974-81. PMID: 19443585.

Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG, Lambin P. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009 Jan;50(1):123-31. PMID: 19091906.

Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody \DN30. Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1857-67. PMID: 18491091.

Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007 Aug;48(8):1313-9. PMID: 17631557.

Perk LR, Visser OJ, Stigter-van Walsum M, Vosjan MJ, Visser GW, Zijlstra JM, Huijgens PC, van Dongen GA. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1337-45. PMID: 16832633.

Börjesson PK, Jauw YW, Boellaard R, de Bree R, Comans EF, Roos JC, Castelijns JA, Vosjan MJ, Kummer JA, Leemans CR, Lammertsma AA, van Dongen GA. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody \U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2133-40. PMID: 16609026.

Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, van Dongen GA. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med. 2005 Nov;46(11):1898-906. PMID: 16269605.

Brouwers A, Verel I, Van Eerd J, Visser G, Steffens M, Oosterwijk E, Corstens F, Oyen W, Van Dongen G, Boerman O. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled \cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm. 2004 Apr;19(2):155-63. PMID: 15186595.

Verel I, Visser GW, Boellaard R, Boerman OC, van Eerd J, Snow GB, Lammertsma AA, van Dongen GA. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med. 2003 Oct;44(10):1663-70. PMID: 14530484.

Verel I, Visser GW, Boerman OC, van Eerd JE, Finn R, Boellaard R, Vosjan MJ, Stigter-van Walsum M, Snow GB, van Dongen GA. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm. 2003 Aug;18(4):655-61. PMID: 14503961.

Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003 Aug;44(8):1271-81. PMID: 12902418.


[8] EATRIS

Becker R, van Dongen GA. EATRIS, a vision for translational research in Europe. J Cardiovasc Transl Res. 2011 Jun;4(3):231-7. PMID: 21544739.


[9] Others

Gholamrezanezhad A. 12 Chapters on Nuclear Medicine. InTech, December 2011. ISBN 978-953-307-802-1.
Open Access book, available for download here.








BV Cyclotron VU is a global health science company that produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Located at the campus of VU University Medical Center in Amsterdam, BV Cyclotron VU produces GMP-compliant medical isotopes in state-of-the-art manufacturing facilities. They are used daily by pharmaceutical and biotechnological companies, medical device manufacturers, hospitals, clinics, and research laboratories.
Order our products directly from one of our distribution partners.